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ABSTRACT 
 
Neurodegenerative disease are frequently characterized by microglia activation and/or 
leukocyte infiltration in the parenchyma of the central nervous system and at the molecular 
level by increased oxidative modifications of proteins, lipids and nucleic acids. NADPH 
oxidases (NOX) emerged as a novel promising class of pharmacological targets for the 
treatment of neurodegeneration due to their role in oxidant generation and presumably in 
regulating microglia activation. The unique function of NOX is the generation of superoxide 
anion (O2
•–) and hydrogen peroxide (H2O2). However in the context of neuroinflammation, 
they present paradoxical features since O2
•–/H2O2 generated by NOX and/or secondary 
reactive oxygen species (ROS) derived from O2
•–/H2O2 can either lead to neuronal oxidative 
damage or resolution of inflammation. The role of NOX enzymes has been investigated in 
many models of neurodegenerative diseases by using either genetic or pharmacological 
approaches. In the present review we provide a critical assessment of recent findings related 
to the role of NOX in the CNS as well as how the field has advanced over the last 5 years. In 
particular, we focus on the data derived from the work of a consortium (Neurinox) funded by 
the European Commission’s Programme 7 (FP7).  We discuss the evidence gathered from 
animal models and human samples linking NOX expression/activity with neuroinflammation 
in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Creutzfeldt–
Jakob disease disease as well as autoimmune demyelinating diseases like multiple sclerosis 
(MS) and chronic inflammatory demyelinating polyneuropathy (CIDP). We address the 
possibility to use measurement of the activity of the NOX2 isoform in blood samples as 
biomarker of disease severity and treatment efficacy in neurodegenerative disease. Finally 
we clarify key controversial aspects in the field of NOX, such as NOX cellular expression in 
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the brain, measurement of NOX activity, impact of genetic deletion of NOX in animal models 
of neurodegeneration and specificity of NOX inhibitors.  
 
Introduction 
The family of NADPH oxidases 
The family of NADPH oxidases (NOX) contains seven members NOX1, NOX2, NOX3, NOX4, 
NOX5, DUOX1 and DUOX2 (for review, see [1]). They are membrane proteins comprising 6 
transmembrane domains (7 for DUOX1 and 2), which have as sole known function to 
catalyze the formation of superoxide anion (O2
•–) and hydrogen peroxide (H2O2). In terms of 
mechanism, all NOX isoforms function as electron transporters. Electrons from cytoplasmic 
NADPH are transferred across membranes by the NOX protein complex, via intermediate 
flavin adenine dinucleotide and heme prosthetic groups, to reduce molecular oxygen in the 
extracellular space or in the lumen of intracellular organelles. During this reaction, oxygen 
and NADPH are consumed while NADP+, intracellular H+ and extra-cytosolic O2
•– are 
produced. O2
•– is rapidly dismutated into H2O2 either spontaneously or upon catalysis by 
superoxide dismutases (SOD). While O2
•– is the primary product of the reaction catalyzed by 
NOX, the kinetics of conversion to H2O2 appears to vary among NOX isoforms. For example, 
only minute amounts of O2
•– and high amounts of H2O2 are detected as a result of NOX4 
activity and only H2O2 is detected from DUOX1 and DUOX2 activities. Each NOX isoform is 
characterized by specific tissue distribution and mechanism of activation [1].  
Because of its high expression and activity in phagocytes, the NOX2 isoform was originally 
named gp91phox (phox: phagocyte oxidase). NOX2 (encoded by the CYBB gene) was identified 
in 1976 [2] and its biochemistry has been extensively studied. At resting state, NOX2 forms a 
stable but inactive complex with the transmembrane protein, p22phox (CYBA). Activation 
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requires protein kinase C-dependent phosphorylation, leading to the translocation of 
cytosolic subunits p47phox (NCF1), p67phox (NCF2) and p40phox (NCF4) to the cell membrane, 
where they physically interact with the p22phox-NOX2 complex and one of the small Rho 
GTP-binding proteins, Rac1 or 2 (Figure 1). Similarly to NOX2, NOX1 and NOX3 require the 
interaction with p22phox and specific cytosolic components (p47phox, p67phox, NOXO1 (NOX 
organizer type 1), NOXA1 (NOX activator type 1)) for activity. NOX4 also requires p22phox, but 
is constitutively active. DUOX1 and 2 require the maturation factors DUOXA1 and 2. NOX5 
and DUOXes are activated by direct phosphorylation and/or increase of intracellular Ca2+. 
Under physiological conditions, NOX are essential mediators of different processes, and 
mutations and polymorphisms of NOX genes can have notable effects [3]. Different 
mutations affecting NOX2 holoenzyme cause increased susceptibility to infections by certain 
pathogens due to deficient neutrophil oxidative burst and impaired bacterial killing in 
humans and mice, a disease known as chronic granulomatous disease [4]. In addition, a 
deficiency in functional NOX2 complex has been associated with the development of various 
autoimmune chronic inflammatory conditions [5]. Mutations in one of the component of the 
DUOX2 complex lead to congenital hypothyroidism while mutations affecting the NOX3 
complex lead to balance impairment in rodents. Mutations in NOX1 predispose patients to 
inflammatory bowel disease [6]. In contrast, loss of function mutations in NOX4, NOX5 or 
DUOX1 genes have not been reported, and the NOX4 and DUOX1 knockout mice do not 
display an obvious spontaneous phenotype. While the absence of at least certain NOX-
derived oxidants have pathological consequences, excessive oxidant production by NOX 
enzymes can contribute to oxidative tissue damage in a wide range of diseases, such as 
cardiovascular diseases [7], pancreatitis [8], and several diabetic complications [9]. 
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Importantly numerous studies have identified the involvement of NOX in various CNS 
disorders [10]. 
Neuroinflammation and neurodegenerative diseases 
The most frequent neurodegenerative diseases (ND) are Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD) and 
multiple sclerosis (MS). Symptomatic treatments exist for some ND like PD and potent 
immunomodulatory drugs show efficacy in MS. However no disease modifying therapies are 
yet available for ND. The symptoms of ND are largely due to the progressive impairment of 
neuronal function and vary depending on the type of neuronal cells and brain regions 
affected (e.g., cortex, hippocampus, substantia nigra, spinal cord, striatum or peripheral 
nerves)  [11-13]. ND can be triggered by cell death, protein aggregation, molecules released 
by injured neurons. The initiating factors leading to neurodegeneration can vary greatly, but 
several features are shared in most ND: abnormal aggregation of specific proteins, spatio-
temporal spreading of aggregated proteins in the CNS parenchyma, a sustained 
inflammatory response, and oxidation of lipids, proteins and nucleic acids [14, 15]. MS 
differs from other ND, as it is an autoimmune disease leading to the destruction of the 
myelin sheath and neuronal loss is secondary to the myelin loss [13]. MS presents typical 
features of inflammation as it is characterized by infiltration of leukocytes in the brain and 
spinal cord. In other ND like AD, PD and ALS, the cell types governing neuroinflammation are 
mostly astrocytes and microglia [14]. Early neuroinflammatory features are mostly 
inconspicuous, as the classical signs of inflammation (calor, dolor, rubor, and tumor) are not 
observed. Moreover, typical anti-inflammatory drugs, such as non-steroidal anti-
inflammatory drugs (most of which inhibit the activity of cyclooxygenase-1 and/or -2) have 
been unsuccessful in treating ND, or have even been harmful [16]. Similar to peripheral 
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inflammation, neuroinflammation is most likely a primary response of the host aimed at 
protecting neurons by removing harmful stimuli and initiating healing processes, However, 
when neuroinflammation is sustained/prolonged, it may become detrimental to neuronal 
cells and contributes to the progression of ND (for review, see [14]. Thus, identifying novel 
drug targets that control neuroinflammation represents an important therapeutic approach 
for ND, although this approach has so far been relatively unexplored [14, 17].  
NOX as potential regulators of neuroinflammation 
Among the potential regulators of neuroinflammation, NOX represent a novel promising 
class of targets for the treatment of ND. As indicated, oxidative modifications to proteins, 
lipids and DNA are almost always observed in ND, but the source of oxidants remains 
elusive. Increased oxidative stress resulting from increased oxidant formation has been 
known for many years to be a central feature in ND [18]. It was once thought that oxidants 
were directly involved in neuronal death due to their toxic properties, but evidence points 
towards subtler regulatory roles of at least some oxidants [19, 20]. Indeed, increased oxidant 
generation in specific cellular and subcellular compartments leads to oxidative modifications 
of macromolecules, which modulate the transcription and other signaling pathways 
controlling neuroinflammation. Oxidants are key components of the neuroinflammatory 
response, but therapeutic approaches targeting reactive oxygen species have so far been 
unsuccessful [18]. In particular, the absence of benefit of antioxidant strategies may be due 
to the fact that the molecules used lacked in vivo efficacy or that the overall effect of 
antioxidants is complicated by a concomitant attenuation of regulatory role of oxidants. A 
novel approach consists of targeting a primary source of O2
•–/H2O2 (e.g., NOX) rather than 
‘scavenging’ oxidants after they have been formed and/or undergone metabolism. 
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There are several potential sources of cellular oxidants, as O2
•–/H2O2 are the byproducts of 
the activity of mitochondria, peroxisomes and xanthine oxidase among others. Compared 
with these sources, however, NOX are different in the sense that their sole function is the 
generation of O2
•–/H2O2. A role of excessive NOX-formed O2
•–/H2O2 and secondary oxidants 
derived from them in CNS pathology is known since the first report that NOX2 gene 
knockout mice are partially protected from brain ischemia [21]. Similar to 
neuroinflammation, which can be protective or deleterious when over-activated, NOX 
present paradoxical features: NOX-derived O2
•–/H2O2 can lead to oxidative damage and 
pathology, or be beneficial by regulating key physiological functions, including the resolution 
of inflammation in autoimmune diseases, including MS. Thus, depending on the pathology, 
the therapeutic approach should either enhance or mitigate NOX activity (see graphical 
abstract). We have previously thoroughly reviewed the literature concerning the expression 
of NOX isoforms in the CNS as well as their presumed contributions to CNS disorders in 
models of AD, PD, ALS and MS [10, 22, 23]. With the present review we would like to provide 
an update on the role of NOX in the CNS as well as how the field has advanced over the last 
5 years. In particular, we focus on key findings obtained by the Neurinox consortium 
(www.neurinox.eu) which had the goal to study some of the most controversial aspects of 
NOX biology in the CNS. 
Advances and findings on NOX in the CNS and ND 
 
1. NOX expression and localization 
The cellular localization of NOX enzymes is still a matter of debate. The scientific literature 
reports the expression of several NOX isoforms in virtually every cell type of the CNS [23]. 
However, many studies were performed by using non-validated commercial antibodies 
without appropriate controls. Validated isoform-specific NOX antibodies are scarce because 
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the lipophilic structure of these proteins makes the generation of specific antibodies 
difficult. Recent available data however have allowed to deduce the precise cellular 
localization of NOX isoforms in the CNS by using a combination of qPCR experiments [24], 
RNAseq analyses of isolated cell types from mouse and human brain [25], and 
immunohistological signals using the few available specific NOX antibodies, which have been 
validated using NOX gene knockout mice [24, 26].  
1.1 NOX2 and NOX4 are the main NOX isoforms expressed in the CNS 
Remarkably, NOX expression data indicate that under physiological conditions most NOX 
isoforms are expressed only to a negligible extent in the CNS. Specifically, qPCR shows that 
NOX1, NOX3, NOX5, DUOX1 and DUOX2 are undetectable or at the limit of detection in the 
human brain as well as in the mouse spinal cord and cerebral cortex [24, 25]. NOX4 is 
detectable, and RNAseq data indicate that it is expressed mostly in the mouse endothelium, 
while very low amounts are also present in fetal astrocytes and oligodendrocytes. Similarly, 
NOX1 and NOX5 are expressed in the vasculature [27], but no clear evidence indicates that 
they are present in CNS parenchyma. Interestingly, DUOXA1 was detected at high levels in 
the CNS by qPCR and RNAseq, most likely in microglia, however only in the mouse brain [24, 
25]. DUOXA1 is known to play a role as maturation factor of DUOX1, but since DUOX1 is 
absent in microglia, it may have a presently unknown role in mouse microglia. Nonetheless, 
the most relevant NOX isoform in the CNS in terms of expression is NOX2. Moreover, NOX2 
expression is strikingly enhanced in the CNS of patients and mouse models of ND [24, 26]. 
1.2 NOX2 and its subunits are enriched in microglia 
Several lines of evidence indicate that, in the CNS, NOX2 is expressed mostly in microglia. 
First of all, NOX2 and subunits are key markers of phagocytes and are under the control of 
the transcriptional factor PU.1, the main transcriptional regulator of phagocytes [28]. In 
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humans, the MoAb 48 monoclonal NOX2 antibody [29] shows distinct cellular co-localization 
of NOX2 with the microglial marker Iba-1, but not with markers for astrocytes (GFAP) or 
neurons (MAP2 or NF) [26]. Although no suitable antibody is available for NOX2 
immunohistochemistry in mice, the following indirect evidence indicate microglial 
expression of NOX2: (i) concomitant increase of NOX2 expression and its subunits p47phox, 
p67phox, p40phox, rac1 and p22phox with the microglial markers CD68, Iba-1 and CD11b in a 
mouse model of ALS [24]; (ii) absence of NOX2 detection in organotypic cerebellar slices 
where microglia was specifically ablated by ganciclovir in tga20/TK mice [22]; (iii) enrichment 
of NOX2 in microglial populations as confirmed by transcriptional profiling of isolated brain 
cells [25]. 
1.3 NOX2 is present in neural adult stem cells 
In addition to microglia, NOX2 is also expressed in small populations of neural stem cells of 
the dentate gyrus and subventricular zone of the adult brain, where NOX2 plays a role in the 
proliferation and multipotency of mouse neural stem cells [30, 31].  
 
Figure 2 summarizes NOX expression in the cells of the CNS. Our analysis cannot exclude the 
possibility that, in specific circumstances (e.g., during neuronal development) or in particular 
subpopulations of cells or brain areas, the expression of NOX isoforms can be elicited, e.g., 
NOX1 in substantia nigra [32] or NOX4 in pericytes [33]. Nevertheless, in ND, the expression 
of NOX2 increases greatly, largely due to microglia activation or CNS invasion by peripheral 
myeloid cells. The latter cannot easily be distinguished from resident microglia, especially in 
pathological situations associated with blood-brain-barrier damage. In any case, it is unlikely 
that NOX2 is a key source of oxidants in mature neurons. Instead, alternative sources of 
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neuronal oxidants might derive from mitochondria [34], MICAL proteins [35], monoamine 
oxidase [36] and cytochrome P450 [37] among others. 
Having clarified that NOX2 expression is closely related to microglia activity offers the 
possibility to better understand and interpret the impact of NOX2 genetic or 
pharmacological targeting. In light of the multifaceted and often discordant consequences of 
microglia contribution in ND, it could then be reasoned that NOX2-derived oxidants in these 
cells can similarly exert beneficial and detrimental effects, depending on the particular 
context. 
2. Small molecules targeting NOX enzymes  
2.1 NOX inhibitors 
Most information on the role of NOX in the CNS derives from studies using the natural 
product apocynin. Numerous published studies report a striking beneficial effect of apocynin 
on ND in animal models, via decreasing microglia activation and improving symptoms and 
survival (reviewed in [22, 38]. However, there are some notable exception to such an 
apparent beneficial effect, including an ALS mouse model where apocynin is inactive [39] 
and the Tg19959 mice model of AD, where apocynin is deleterious [40]. Importantly, we [41] 
and others [42] have shown that apocynin is not a NOX inhibitor in the sense that it does not 
show affinity for the NOX enzyme. Apocynin may appear as a NOX inhibitor at high 
concentrations because either it interferes with peroxidase-dependent assays for oxidants 
[43] or may inhibit the translocation of p47phox in neutrophils, thereby indirectly inhibiting 
NOX2 activation [44]. A recent study using a mitochondria-targeted apocynin argues for 
mitochondrial oxidant scavenging as the basis for its anti-inflammatory and neuroprotective 
effects in a mouse model of PD [45]. Thus, studies documenting a therapeutic effect of 
apocynin in models of neurodegenerative diseases do not necessarily imply a role of NOX.  
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The case of apocynin highlights the challenges faced when searching for NOX inhibitors. This 
is the reason why we [41, 46, 47] and others [48] have developed a strict flowchart for 
identification and characterization of NOX inhibitory molecules [49]. This approach is 
designed to exclude false positives including those resulting from cell toxicity and 
interference with oxidant-measuring systems (Figure 3). This flowchart emphasizes the 
requisite of (i) using NOX cell free assays for screening small molecules and determines the 
mode of action of identified inhibitors, (ii) use several detection systems to measure the 
activity of NADPH oxidases, ideally by separately measuring O2
•– and H2O2, (iii) use of 
methods allowing measuring NOX-dependent substrate consumption (i.e. O2 and NADPH) to 
exclude molecules interfering with ROS detection systems and (iv) importantly for the 
development of NOX based drugs, clear documentation of in vivo pharmacokinetics and 
pharmacodynamics parameters.. Bona fide NOX inhibitors should have the two following 
characteristics:  i) they should inhibit NOX-derived oxidants in both cellular and NOX purified 
membranes and ii) they should block oxygen consumption in cells and/or NADPH 
consumption in NOX purified membranes. Below is an exhaustive list of small molecules NOX 
inhibitors which have passed this flowchart. 
(i) Diphenyleneiodonium (DPI) potently inhibits all NOX isoforms with high affinity [46], most 
likely by irreversible binding to the cytosolic FAD domain of NOX [50]. However DPI lacks 
drug-like properties due to mitochondria toxicity and low solubility. DPI is not specific for 
NOX as it inhibits other electron transport chains, including NO synthase, xanthine oxidase 
among others. Nonetheless DPI is a useful pharmacological tool in vitro and should be 
systematically used as a reference NOX inhibitor. As a rule of thumb, a signal not inhibited by 
DPI is most likely not due to NOX [49]. However caution is still warranted in interpretation 
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since a lucigenin bioluminescent signal inhibited by DPI was recently shown to be due to 
cytochrome P450 [51]. 
(ii)  GSK2795039, a novel drug-like small molecule, is the first identified NOX inhibitor to 
show isoform-specificity. Its mode of action is through competition for the NADPH binding 
site of NOX2. GSK2795039 is orally available, non-toxic, CNS-permeable and inhibits NOX2 
activity in vivo [41]. GSK2795039 has not yet been tested in an animal model of ND.  
(iii) A subset of N-substituted phenothiazines - but not non-substituted phenothiazines - 
inhibits NOX activity [47]. N-substituted phenothiazines have been used for decades as anti-
psychotic agents, and upon administration can give rise to micromolar concentrations in the 
CNS. It remains unclear how N-substituted phenothiazines inhibit NOX, although they do not 
show isoform specificity. N-substituted phenothiazines, including thioridazine and 
perphenazine, are known to be promiscuous molecules with numerous potential modes of 
action in the CNS. However, since they are already used as human therapeutics, they offer 
an attractive perspective for potential repurposing in ND (see below for their use in a mouse 
model of ALS). 
(iv) Ebselen and ebselen-sulfur analogues (e.g. thr101) were identified as inhibitors of the 
interaction between p22phox and p47phox in a high throughput screening [52]. These 
molecules inhibit NOX2 in a membrane assay and all NOX isoforms and in whole cells 
expressing NOX1, NOX4 and NOX5. Although low concentration of ebselen is toxic to cells, it 
was confirmed as bona fide inhibitor of NOX2 in precedent [53] and subsequent [48] studies. 
Ebselen is known for a long time for its neuroprotective properties, in particular against 
stroke [54]. Unfortunately ebselen has multiple potential pharmacological targets with a 
strong redox component [55] and is thus not very useful to demonstrate a NOX-dependent 
activity. 
 
 
13 
 
(v) Celastrol is a natural extract derived from Tripterygium wilfordii, a plant used in 
traditional Chinese medicine. Celastrol inhibits NOX2–derived ROS and substrate 
consumption in NOX2 membrane assays and cells expressing NOX1, NOX2, NOX4 and NOX5, 
including NOX2-dependent oxygen consumption in neutrophils and NADPH in NOX2 
membrane assay [41, 46]. However, its practicality as a NOX inhibitor is limited due to cell 
toxicity, the fact that it is colored (orange) and thus interferes with several assays.  Similarly 
to ebselen, it is a promiscuous molecule with multiple described mode of action and is 
therefore not very useful to demonstrate a NOX-dependent activity. 
Recently, the team of Zielonka and Kalyanaraman have developed their own flow-chart to 
identify NOX2 inhibitors using HL60 cells, a human neutrophil-like cell with high levels of 
NOX2 expression and activity [48, 56].  They use several distinct read-outs for O2
•– and H2O2 
in high throughput format and confirm the hits by measuring toxicity and NOX2-dependent  
oxygen consumption by HL60 cells. This approach confirmed the activity of DPI as well as 
ebselen and analogues but infirmed the NOX inhibitory of apocynin. It also allowed the 
identifiication of several novel small molecules, including a novel small molecule of great 
interest Thioxo-dihydroquinazolin-one (aka compound 43) [48]. Identified molecules now 
awaits confirmation in NOX2 semi-recombinant assays and potential mode of action. 
The favorable impact of antioxidants and anti-inflammatory molecules like apocynin adds 
further evidence that targeting neuroinflammation and oxidative stress may be beneficial in 
ND. The potential therapeutic values of apocynin and other reported non-validated NOX 
inhibitors is not questioned, but their efficacy in a model of ND is not sufficient evidence of a 
role of NOX and should be interpreted with caution. Only the use of CNS-permeable and fully 
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validated NOX inhibitors, such as GSK2795039 will provide valid information on the role of 
NOX2 in ND. 
2.2 NOX activators 
Only few attempts have so far been made to identify substances inducing NOX2 activity for 
treating inflammatory disease although small molecules that activate ROS production have 
previously been identified [57-61]. Quinolinone derivatives are a new class of molecules that 
enhance NOX2 function has been recently developed aiming for treatment of CNS 
autoimmune diseases [62]. Identified NOX agonists are currently in a phase of optimisation 
for bioavailability and pharmacokinetics. They have anti-inflammatory properties and are 
able to decrease the pro-inflammatory role of TNF-α in the low nanomolar range. Future 
studies will show whether they are suitable for clinical use as first in class NOX2 activators 
for treatment of autoimmune diseases. 
3. Mechanisms regulated by NOX2 in peripheral circulating cells and autoimmune disease 
 
In reference to the scheme in the graphical abstract, a large part of Neurinox effort was 
dedicated to the study of the oxidants generated by NOX enzymes in the context of 
autoimmune diseases, including MS, and other peripheral autoimmune demyelinating 
diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP) and Guillain-
Barré syndrome (GBS). More specifically, NOX2 activity in macrophages and other antigen 
presenting cells has an anti-inflammatory effect and regulate activation of autoreactive T 
cells [63]. This unexpected fact was originally discovered in a genetic study performed to 
identify the most important polymorphic loci controlling autoimmune chronic inflammatory 
diseases, using models for rheumatoid arthritis and multiple sclerosis [64]. This led to the 
identification of a polymorphism in the coding sequence of Ncf1 (neutrophil cytosolic factor 
1), the gene coding for p47phox, a subunit essential to control NOX2-dependent formation of 
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O2
•– [64, 65]. It has been estimated that approximately half of inbred rat strains and half of 
the wild rat population carries an allele in Ncf1 that leads to a significantly lower NOX2-
mediated oxidative burst [66]. The regulatory role of oxidants is likely to be conserved 
between species. Consistent with this notion, there is also an extensive polymorphism in the 
human Ncf1 region which is associated with autoimmune diseases [67]. Importantly, this 
allele confers strong protection against autoimmune diseases. This finding opened the 
provocative possibility that NOX agonists could serve as therapeutics in autoimmune 
disorders [68]. Since then, a protective role of NOX2-derived oxidants has been reproduced 
in several different models of autoimmune disorders, including models for MS and Guillain 
Barré [69-71]. The NOX2-dependent anti-inflammatory effect is mediated by several 
different pathways: (i) downregulation of autoreactive T cells during antigen presentation 
[63]; (ii) autocrine downregulation of inflammatory macrophages [5] [72]; (iii) 
downregulation of STAT1 mediated activation of the interferon pathway [73, 74]; and (iv) 
promotion of a protective effect by neutrophil extracellular traps (NETS) formed by 
neutrophils [75] . Further studies aimed to identify both the chemical nature of the oxidants 
involved and the respective roles played by these potentially protective pathways in MS and 
peripheral neuropathies are needed. Indeed, it is still unclear at present if excess oxidants in 
the CNS are counteracting the protective effect of the peripheral inflammatory attack, 
thereby promoting neurodegeneration [76].  
4. Genetic and pharmacological inhibition of NOX in models of ND 
The contribution of NOX-derived oxidants to the development of ND was studied in detail in 
two models of ND known for their intense neuroinflammatory reaction: ALS and Creutzfeldt–
Jakob disease (CJD).   
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ALS is a severe ND affecting motoneurons and leading to complete paralysis and death. ALS 
is a typical neuroinflammatory disease characterized by an increase in pro-inflammatory 
markers, microgliosis and astrocytosis. In most cases, the underlying causes of ALS are 
unknown. However, the identification of novel ALS-causing mutations indicates that 
mechanisms leading to the aggregation of specific proteins and RNA pathology (e.g., TDP-43, 
SOD1, FUS and c9orf72) are a key pathological event in ALS.  There are no treatments for 
ALS, and Riluzole, a small molecule known to decrease glutamate levels in the CNS, is the 
only drug prescribed for ALS patients, although it has very modest efficacy. In both patients 
and animal models of ALS, the expression of microglial NOX2 is strongly increased, 
specifically in affected regions of the spinal cord [24]. Furthermore, previous studies by the 
Engelhardt group have shown that NOX1 and NOX2 deficiency confers prolonged survival of 
transgenic mice expressing an ALS-causing mutation (SODG93A mice), the most commonly 
used model for this disease [77]. NOX inhibitors appeared as most promising therapeutics to 
slow down ALS progression. As mentioned above, thioridazine and perphenazine have NOX 
inhibitory activity and as they are used in the treatment of humans, they represent attractive 
drugs for rapid initiation of clinical trials in ALS patients [47]. However, administration of 
thioridazine and perphenazine to SODG93A mice did not improve survival, although they 
showed some benefits in secondary read-outs, such as motor function for thioridazine and 
weigh loss for perphenazine [47]. Thioridazine decreased O2
•- levels and microglia activation 
markers in spinal cords of SODG93A mice, yet crossing of SODG93A mice with NOX2 or NOX1 
gene knockout mice did not affect disease onset and progression, nor microgliosis, 
astrogliosis or motoneuron survival [24]. These results thus question initial reports [77], 
showing a prolonged lifespan in ALS models related to NOX2 and NOX1 deficiency.  
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Creutzfeldt–Jakob disease (CJD) is an incurable ND characterized at the neuropathological 
level by a massive neuronal loss conferring a spongiform aspect of the brain [78]. The 
causative agent of CJD is the misfolding of prion proteins which propagates among neurons 
and leads to a neuroinflammatory environment and increased microglial NOX2 expression 
[26]. Interestingly, NOX2 gene knockout mice infected with prions did not show decreased 
microgliosis, but showed a transient improvement of motor function (rotarod), decreased 
oxidants, significant survival improvement and improvement of vacuoles formation in the 
brain at terminal stage. Similarly, NOX2 greatly contributes to neurotoxicity in mice treated 
with a neurotoxic anti-prion antibody [79]. 
Together, these data show that NOX2 expression is increased strongly in ND and most likely 
contributes to oxidant formation associated with neurodegenerative mechanisms, although 
it does not seem to limit microglia activation and microgliosis. Whereas increased NOX2 
activity and oxidant generation are shared between CJD and ALS, NOX2 deletion slightly 
improves survival only in CJD. This suggests that the neurotoxic cascade of CJD and ALS are 
different, and that targeting NOX2-derived oxidants might be more efficient in CJD than in 
ALS. Remarkably, while antioxidant-based therapies have been strikingly unsuccessful in ALS, 
prion pathogenesis was shown to converge in oxidant formation and to be efficiently 
mitigated both ex vivo and in vivo by antioxidants [80]. Therefore, novel specific NOX2 
inhibitors with blood brain barrier permeability and a defined mode of action such as 
GSK2795039 await further testing in prion pathogenesis and other ND [41, 81]. 
5. Measurement of NOX activity in vivo  
Measuring NOX activity in tissues remains a challenge. In the literature of ND the most 
commonly used approach is to use a CNS tissue homogenate to which lucigenin and NADPH 
are added and lucigenin-enhanced chemiluminescence is then determined as a measure of 
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O2
•–. However, the method of lucigenin-enhanced chemiluminescence has well known 
pitfalls and limitations (see, e.g., [82]). In addition, Rezende et al. [51, 83] recently reported 
that the signal measured in this assay is due to cytochrome P450, rendering it inappropriate 
for determination of NOX activity. 
The major product of NOX is O2
•–, , and Hydroethidine or dihydroethidium [84] is considered 
the ‘gold standard’ for O2
•– determination in biological systems [85]. Importantly, previous 
work by Kalyanaraman and co-workers has established that the fluorescence of ethidium, 
commonly the most abundant oxidation product of hydroethidine in biological systems, is 
not specific for O2
•– [84]. Instead 2-hydroxyethidium is the O2
•– specific product. 
Unfortunately, ethidium and 2-hydroxyethidine have very similar fluorescent properties, so 
that fluorescence is not a specific readout for O2
•– in biological systems. Rather, a 
combination of chromatographic separation of ethidium and 2-hydroxyethidine coupled 
with fluorescent or mass spectrometry based detection is required for the selective 
determination of O2
•–. Using LC-MS/MS and administering hydroethidine into the spinal cord 
revealed that thioridazine decreased O2
•– in the spinal cord of SOD1G93A mice in vivo [24]. 
Despite this successful demonstration of a localized decrease in O2
•– in vivo, there remain a 
number challenges. First, such approach cannot provide direct information on NOX activity, 
as the method at best measures steady state concentration of O2
•–, that is determined by 
the rates of both formation and ‘removal’ of this reactive species. ‘Removal’ in this context 
includes both dismutation of O2
•– as well as reaction of O2
•– with other reactive species (e.g., 
nitric oxide) giving rise to secondary oxidants. Second, the concentration of 2-
hydroxyethidine detected following in vivo administration of hydroethidine represents a 
snapshot only of what is likely a complex and changing process as ND develops. Similarly, the 
route of administration of hydroethidine likely affects the products detected subsequently. 
 
 
19 
Therefore, for such a probe-based approach to measure O2
•–, each experimental model 
requires careful ‘optimization’ with regards to timing of probe administration relative to 
disease process, route of probe administration, and exposure time prior to tissue harvest 
and analytical analyses of unreacted and reacted probe. Third, the biochemical approach 
cannot provide true information on the spatial compartmentalization of NOX activity. 
As of today, no method allowing for the live measurement of reactive oxygen species or NOX 
activity in the CNS is available. Such a probe would help understanding the respective 
sources of oxidants, their dynamics, prognosis value of NOX2 activity and contribution to ND. 
6. NOX and oxidative biomarkers in NDs 
Despite the challenges mentioned above, a large part of Neurinox was dedicated to evaluate 
NOX activity and oxidized biomarkers in ND patients. In a clinical study, NOX2 activity from 
peripheral neutrophils and monocytes was directly measured in fresh whole blood of a 
cohort of 83 ALS patients, and age- and gender-matched healthy controls. The assay is based 
on flow cytometry and uses the cell permeable fluorescent dye DHR123, an unspecific probe 
used for diagnosis of chronic granulomatous disease. Upon addition of a specific activator, 
no difference was observed between patients and healthy controls, however, inside the ALS 
group, low DHR123 oxidation in leukocytes was significantly associated with a longer survival 
[86]. This represents an important finding in the field of ALS because this may be a prognosis 
biomarker of the severity of ALS. More importantly, such a measure could be implemented 
as surrogate biomarker to address the benefit of a drug in clinical studies (Figure 4A-C). 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder 
characterized by damaged myelin sheath of the peripheral nerves leading to progressive 
weakness and impaired sensory function in the legs and arms. Intravenous immunoglobulin 
(IVIg) therapy is used as a first-line therapy and usually provides substantial benefit to 
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patients. A prospective clinical study enrolled 30 CIDP patients treated with IVIg and 30 
control subjects for whom NOX2 activity/DHR123 oxidation was measured in neutrophils and 
monocytes from freshly collected blood. At diagnosis NOX2 activity was significantly 
increased in CIDP patients compared to controls. However, following IVIg therapy, NOX2 
activity was even more increased compared to basal levels [87]. The exact cause of this 
observation is unclear, but the results are consistent with therapeutic improvement in 
autoimmune demyelination being associated with enhanced NOX2. Because of the simplicity 
and robustness of this assay, it could be included systematically in clinical settings for ND. 
This would potentially provide key information on inclusion criteria and the response to a 
drug. 
Measuring NOX2 activity in whole blood is informative of a stage of disease. However, as 
previously stated, there are currently no methods/probes available to measure O2
•– or H2O2 
in human CNS. For these reasons, determining the role of NOX in human ND continues to 
rely on indirect measures, such as assessment of oxidative stress. The Neurinox consortium 
determined F2-isoprostanes as well as enzymatic oxidation products of arachidonic acid (by 
LC-MS/MS) in cerebrospinal fluid and plasma of patients with progressive multiple sclerosis. 
Compared with controls, plasma concentrations of F2-isoprostanes and prostaglandin F2 
(PGF2) were decreased with increasing disability score [88]. This was in contrast to the 
situation in cerebrospinal fluid, where the concentrations of PGF2, but not F2-isoprostanes, 
were significantly higher in patients with progressive disease than controls. Cerebrospinal 
fluid PGF2 was reduced with natalizumab and methylprednisolone treatment, suggesting 
that PGF2 levels in the CSF represents reliable surrogate biomarkers for evaluation of the 
efficacy of a drug (Figure 4D, E). Note that PGF2 levels remained unaffected by the use of 
nonsteroidal anti-inflammatory drug in secondary progressive MS. Interestingly, 
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cerebrospinal fluid PGF2 did not associate with validated cerebrospinal fluid markers of 
inflammation or markers of brain damage that themselves did not associate with the 
disability score [88]. These results suggest that MS progression is associated with low rather 
than high systemic oxidative activity, and that this may play a role in immune dysregulation 
with central nervous system inflammation accompanied by increased local cyclooxygenase-
dependent lipid oxidation. 
 
Other redox systems in the CNS 
The therapeutic approach of targeting proteins involved in redox dysregulation in ND is not 
limited to NADPH oxidases and several redox systems represent valid pharmacological 
targets. Dimethyl fumarate, a small molecule activator of Nrf2, a key transcription factor of 
the antioxidant response, has shown promising results for the treatment of certain forms of 
MS [89]. Similarly, mitochondrial targeting of specific antioxidants [90] and apocynin [91] 
have been reported to yield promising results in preclinical models of PD. Small molecules 
inhibiting myeloperoxidase are in clinical trials for PD [92]. In the CNS, H2O2 can be 
generated by the MICAL (molecule interacting with CasL) family of enzymes, in particular by 
MICAL-2 which controls dendrite and synapse formation [93]. In addition to NOX, several 
sources of O2
•–/H2O2, including nitric oxide synthase, monoamine oxidase, xanthine oxidase 
are present in the CNS, mainly in microglia [94]. Reversible cysteine oxidation by 
thioredoxins and peroxiredoxins are increasingly recognized as a fine-tuning redox 
regulation of CNS homeostasis, similar to what is known for phosphorylation. Figure 5 
summarizes the main localization of several of these oxidant generators and redox 
regulators. 
 
Concluding remarks  
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Our recent work has clarified NOX localization in the CNS, identified novel small molecule 
NOX inhibitors/activators and state-of-the-art methods to measure O2
•– in vivo, showed a 
strong association between NOX2 and disease progression in ND, and indicated that NOX2 
expression and activity parallels microgliosis and neuroinflammation in ND. Importantly, 
however, inhibition of NOX provided at best only limited beneficial effects in mouse models 
of ALS and CJD. Although some neurodegenerative processes (e.g. following traumatic brain 
injury) may benefit from NOX2 inhibition, it appears that this is not a disease-modifying 
approach. The question as to whether Nox2-generated oxidants is beneficial, not functional 
or detrimental in neuropathology should be addressed in priority using NOX2-deficient mice 
in animal models of ND.  
Despite the scientific progress, no current therapeutic is able to halt neurodegenerative 
processes, in part due to difficulties in our understanding of the mechanisms underlying the 
development of ND. Indeed, the identification of potential therapeutic targets derives from 
neuropathological observations and identification of disease-causing mutations. However, 
the fact that a particular pathological characteristic, such as oxidative stress, is associated 
with disease progression does not mean that it is a cause of the disease (see review [19]). 
For example, the presence of -amyloid aggregates is the most clear pathological signs 
related to AD, however, it is not yet clear whether therapies decreasing -amyloid 
aggregates in AD patients translate into symptomatic improvement and doubts arise about 
the validity of the original hypothesis implying amyloid as major cause of the disorder [95-
97]. Similarly, the increase in number of glial cells with altered morphological status in brain 
sections of different patients affected by ND has supported the idea that this reaction 
contributes to disease progression. Experimental evidence has shown that the pathogenic 
mechanisms are more complex. Indeed, microglia can exert both detrimental and protective 
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functions, depending on the particular pathological context [14]. It appears that similar 
conclusions can be taken for NOX in ND. NOX2 up-regulation is indeed a common feature of 
ND and a sign of a neuroinflammatory response, but NOX2 inhibition is not a disease-
modifying treatment. NOX2 upregulation, increased oxidant generation, microgliosis and 
neuroinflammation are all associated factors of ND, but this evidence does not necessarily 
mean that they are a cause, as they can be rather a consequence of the neurodegenerative 
process. However, one of the key findings of our studies shows that a correlation between 
NOX2 activity and disease progression or response to treatments in patients is measurable in 
the blood, which makes NOX2 a promising biomarker for future evaluation of therapies for 
ND. Understanding the kinetics of oxidant formation and metabolism, the relative role of 
various oxidant-generating systems and their inter-dependence in the fine redox regulation 
will pave the way for long awaited therapeutics targeting oxidative stress in CNS disorders. 
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Figure legends 
 
Graphical abstract: Generation of oxidants by NOX follows a Gaussian distribution in the 
general population, where both extremes of the bell-shaped curve are considered to 
promote neurodegenerative diseases. Too little NOX2 activity promotes autoimmune 
neurodegeneration while too much NOX2 activity promotes microglia-dependent 
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neurodegenerative mechanisms. The arrows represent potential therapeutic approaches to 
reach normal redox function in the CNS. 
 
Figure 1: Schematic structure of the phagocyte NADPH oxidase NOX2. The catalytic complex 
is formed by the membrane association of NOX2 and p22phox. Upon activation a cytosolic 
complex is formed and translocates to the membrane in order to form an active O2
•–-
generating enzymatic system. 
 
Figure 2: Cellular localization of NOX2 in the CNS. NOX2 is expressed by microglia and 
invading monocytes/macrophages as well as adult neural stem cells. All other NOX isoforms 
are present in brain vascular cells. 
 
Figure 3: Flow-chart for identification of bona fide NOX inhibitory drugs. 
 
Figure 4: Measurement of redox activity in physiological fluids of patients affected by 
neurodegenerative as predictors of disease severity and potential efficacy of a drug 
(surrogate biomarkers). NOX2 activity can be measured directly in whole blood using DHR123 
(A) followed by flow cytometry (B). High levels of NOX2 activity is associated with decreased 
survival in ALS patients (C) [86]. Quantification of oxidation products of arachidonic acid in 
the cerebrospinal fluid of MS patients (D) shows that it can serve as surrogate biomarkers of 
the activity of a drug treating MS (E) [88].  
 
Figure 5: Oxidant generating and redox regulating systems potentially involved in oxidative 
stress-mediated neuroinflammation (see text for details). 
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